ALLMedicine™ Waldenstrom Macroglobulinemia Center

Feb 24th, 2023 - Phase 1a is a dose escalation to evaluate the safety and tolerability of NX-2127 in adult patients with relapsed/refractory (R/R) B-cell malignancies, who have required and received at least 2 prior systemic therapies (or at least 1 prior therapy ...

Feb 23rd, 2023 - Waldenstrom's macroglobulinemia (WM), also known as lymphoplasmacytic lymphoma, is a type of non-Hodgkin's lymphoma in which the malignant cells produce many macroglobulin proteins. It originates from B cells and develops in the bone marrow, where...

Feb 17th, 2023 - Monoclonal gammopathy of undetermined significance (MGUS) is a benign hematological condition with the potential to progress to malignant conditions including multiple myeloma and Waldenstrom macroglobulinemia. Medications that modify progression ...

Feb 8th, 2023 - The purpose of this protocol is to collect blood, tissue (bone marrow and lymph node biopsies) and/or imaging studies (PET and CT scans) from patients with monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia/small lymphocytic lymph...

Feb 8th, 2023 - Description: This study aims to determine vaccine titers in B-cell malignancies; specifically, in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), or other non-Hodgkin lymphomas (NHL) [follicular lymphoma (FL), mantle cell lymp...

Feb 24th, 2023 - Phase 1a is a dose escalation to evaluate the safety and tolerability of NX-2127 in adult patients with relapsed/refractory (R/R) B-cell malignancies, who have required and received at least 2 prior systemic therapies (or at least 1 prior therapy ...

Feb 8th, 2023 - The purpose of this protocol is to collect blood, tissue (bone marrow and lymph node biopsies) and/or imaging studies (PET and CT scans) from patients with monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia/small lymphocytic lymph...

Feb 8th, 2023 - Description: This study aims to determine vaccine titers in B-cell malignancies; specifically, in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), or other non-Hodgkin lymphomas (NHL) [follicular lymphoma (FL), mantle cell lymp...

Jan 12th, 2023 - AT rich interacting domain containing protein 1A (ARID1A) is a tumor suppressor gene frequently mutated in solid tumor malignancies, often loss of function mutations (frameshift or non-sense). ARID1A encodes a large nuclear protein BAF250a, a vita...

Jan 6th, 2023 - PRIMARY OBJECTIVE: I. To determine the efficacy (as assessed by complete response [CR] rate) of the combination of ixazomib citrate (ixazomib) and ibrutinib in Waldenstrom macroglobulinemia (WM) patients. SECONDARY OBJECTIVES: I. To assess the ove...

Sep 1st, 2022 - Background Schnitzler syndrome is a rare, auto-inflammatory syndrome associated with IgM monoclonal gammopathy that manifests as a non-pruritic urticarial rash. Patients may also have intermittent fevers, lymphadenopathy, bone pain, and arthralgia.

Aug 19th, 2022 - Anthony R. Mato, MD, MSCE: Matt, let's confuse the situation even further. We have the ELEVATE-RR [trial] (NCT02477696) as well, so we have ibrutinib vs zanubrutinib, [and] we have ibrutinib vs acalabrutinib. How do we sort out ELEVATE-RR in the c...

Aug 19th, 2022 - Anthony R. Mato, MD, MSCE: I want to switch gears now and talk about zanubrutinib. Alexey, we have some longer-term follow-up data for zanubrutinib that was presented at EHA (European Hematology Association) [2022 Congress]. Can you comment on tha...

Aug 9th, 2022 - Data from the following clinical trials are discussed: ASCO 7521: ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM) EHA P1120: The E...

Aug 1st, 2022 - The FDA has granted an orphan drug designation to the CD20-targeted autologous CAR T-cell therapy, MB-106, for use as a potential therapeutic option in patients with Waldenström macroglobulinemia.1 The product was developed by Brian Till, MD, a...